WEDNESDAY, June 5 (HealthDay News) -- A new therapy for multiple
sclerosis that teaches the body to recognize and then ignore its
own nerve tissue appears to be safe and well-tolerated in humans, a
small new study shows.
If larger studies prove the technique can slow or stop the
disease, the therapy would be a completely new way to treat
autoimmune diseases such as multiple sclerosis (MS) and type 1
Most treatments for MS and other autoimmune diseases work by
broadly suppressing immune function, leaving patients vulnerable to
infections and cancers.
The new treatment targets only the proteins that come under
attack when the immune system fails to recognize them as a normal
part of the body. By creating tolerance to only a select few
proteins, researchers hope they will be able to cure the disease
but leave the rest of the body's defenses on guard.
"This is important work," said Dr. Lawrence Steinman, a professor of neurology at Stanford University who was not involved with the study.
"Very few investigators are trying therapies in humans aimed at simply turning off unwanted immune responses and leaving the rest of the immune system intact to fight infections -- to do surveillance against cancer," Steinman said. "The early results show encouragement."
For the study, published in the June 5 issue of the journal
Science Translational Medicine, researchers in the United
States and Germany recruited nine patients with MS. Seven had the
relapsing-remitting form of the disease, while two others had
secondary progressive MS (a more advanced phase). All were between
the ages of 18 and 55, and were in good health except for their
Blood tests conducted before the treatments showed that each
patient had an immune reaction against at least one of seven myelin
Myelin is a white tissue made of fats and proteins that wraps
nerve fibers, allowing them to conduct electrical signals through
the body. In MS, the body attacks and gradually destroys these
myelin sheaths. The damage disrupts nerve signals and leads to
myriad symptoms, including numbness, tingling, weakness, loss of
balance and disrupted muscle coordination.
Six patients in the study had low disease activity, while three
others had a history of more active disease. Most were not
experiencing symptoms at the time of their treatment.
On the day of the treatments, patients spent about two hours
hooked up to a machine that filtered their blood, harvesting white
cells while returning red cells and plasma to the body.
After the white cells were collected, they were washed and then
combined with seven proteins that make up myelin tissue. A chemical
was used to link the proteins to the white blood cells, which were
In addition to fighting germs, another important role of the
immune system is to get rid of dead and dying tissues. When these
tissues are collected by the spleen, it sends out a signal to the
rest of the immune system that the dying tissues are just harmless
The new treatment aims to take advantage of the body's waste
disposal system. In attaching the myelin proteins to dying white
blood cells, the idea is to get the body to also recognize those
proteins as harmless and hopefully leave them alone.
In animal models of MS, the same group of researchers has shown
that using this system to induce immune tolerance can stop the
progression of disease.
This was the first test of this kind of therapy in humans, and
although the study was too small to show whether the treatment
changed the course of the disease, researchers did see some
Blood tests taken before and after the treatment showed that the
infusions turned down immune reactivity to myelin proteins, but
didn't affect the immune response to potential infections, like
"We were only trying to turn down the myelin responses, which we did," said study researcher Stephen Miller, a professor of microbiology and immunology at the Northwestern University Feinberg School of Medicine, in Chicago. "And we didn't turn down the response to tetanus. That suggests ... that this therapy, just like in mice, can induce tolerance in humans."
Patients reported mild and moderate side effects during their
treatments. Nearly all these problems, except for a metallic taste
in the mouth, were judged to be unrelated to the study
The six patients with mild disease activity showed no new
symptoms or worsening in their conditions three months after the
infusions. What's more, MRI scans showed no new areas of
inflammation after their treatments.
Two of the three patients with more active disease had worsening
symptoms within two weeks of treatment. Those symptoms cleared up
with steroid treatments. MRI scans showed all three patients
developed new lesions that indicated a worsening of
None of the patients lost neurologic function during the six
months they were followed after their treatments.
"Whether it's going to have a longstanding effect, or an effect in locking down the disease symptoms in MS patients, is going to take a phase 2 or phase 3 trial," said Miller, who disclosed that he shares rights to a patent on the technique.
The study was supported by private grants from foundations in
Germany and the United States, and by funding from the German
For more information on immune tolerance therapies, head to the
U.S. National Institute of Allergy and Infectious
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.